ARTICLE | Management Tracks
Plus: Fujimoto to lead Takeda-Astellas-Sumitomo’s JV, and updates from Sofinnova Partners, SystImmune, Amarna and Cytonus
By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
April 23, 2024 12:35 AM UTC
Anthos Therapeutics Inc. named Bill Meury to succeed founding CEO John Glasspool, who will join Blackstone Life Sciences as an operating adviser. Meury, who was CEO of Karuna Therapeutics Inc. before it was acquired by Bristol Myers Squibb Co. (NYSE:BMY), will also join Anthos’ board. Blackstone Life Sciences founded Anthos, a cardiovascular disease company, alongside Novartis AG (SIX:NOVN; NYSE:NVS) in 2019.
Toshio Fujimoto will become CEO of a joint venture of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK), Astellas Pharma Inc. (Tokyo:4503) and Sumitomo Mitsui Banking Corp. that will incubate early discovery programs primarily originating from Japan. Fujimoto was CEO of iPark Institute Co. Ltd., the company in charge of managing Shonan Health Innovation Park, a pharmaceutical-initiated science park established in 2018…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652195/bill-meury-named-ceo-of-anthos